Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Randomized Phase II Study Assess the Schema of Retreatment With Lutathera® ([177LU]LU-DOTA-TATE) in Patients With New Progression of Intestinal Well-differenciated Neuroendocrine Tumor

NCT04954820 is registered in ClinicalTrials.gov with Institut du Cancer de Montpellier - Val d'Aurelle as lead sponsor.

NCT NCT04954820
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04954820 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Randomized Phase II Study Assess the Schema of Retreatment With Lutathera® ([177LU]LU-DOTA-TATE) in Patients With New Progression of Intestinal Well-differenciated Neuroendocrine Tumor
Lead sponsor
Institut du Cancer de Montpellier - Val d'Aurelle
Phase
Phase 2
Overall status
Recruiting
Start date
October 18, 2021
Completion date
October 31, 2033
Enrollment
146 (estimated)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

intestinal well differentiated endocrine tumor, neuroendocrine tumors, progressive disease